Product Description
NVP Healthcare was developing nvp-1205, an oral NPC1L1 Blocker,HMG-CoA Inhibitor for Dyslipidemia
Mechanisms of Action: NPC1L1 Blocker, HMG-CoA Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NVP Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Dyslipidemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02029625 |
NVP-1205 | P1 |
Completed |
Dyslipidemia |
2014-03-01 |
2022-04-06 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|